Shares of Xenon Pharmaceuticals (XENE) have gained approximately 20% over the past three months, primarily driven by positive top-line data from the X-TOLE2 study evaluating its lead candidate, ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

Today, a brief rundown of news from Xenon Pharmaceuticals and Capricor Therapeutics, as well as updates from Pfizer, Regeneron, AbbVie and GSK that you may have missed. Expected readouts in obesity, ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7%. Xenon Pharmaceuticals believes this is the highest such efficacy ...

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...

Xenon Pharmaceuticals Inc. XENE-Q stock soared Monday after the Canadian drug developer reported better-than-expected results from a late-stage human trial for its epilepsy treatment. Burnaby, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co ...

Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly ...